Physician profile
John Baker
NPI 1760423339
$473.99
in general payments reported to CMS, 2019-2025
12 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.80 · 2023: $66.21 · 2024: $42.55 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $457.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $146.36 | 2025 | |
| Lundbeck LLC | $85.64 | 2024-2025 | Rexulti |
| Octapharma USA, INC. | $66.21 | 2023 | Panzyga |
| Lilly USA, LLC | $32.92 | 2025 | Jardiance, Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $22.45 | 2025 | Symbravo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.93 | 2025 | Xifaxan |
| Abbott Laboratories | $19.63 | 2025 | |
| Merz Pharmaceuticals, LLC | $19.49 | 2024 | Ampyra |
| Emd Serono, INC. | $16.80 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.84 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $14.55 | 2025 | |
| Exact Sciences Corporation | $14.17 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.